## **Core Concept**
The question tests knowledge of pharmacological properties of different insulin formulations, specifically their durations of action. Insulins are classified based on their onset, peak, and duration of action, which guides their use in managing diabetes mellitus.

## **Why the Correct Answer is Right**
Lantus (Glargine) is a long-acting insulin analog. It has a mechanism of action that provides a relatively constant level of insulin activity over 24 hours, with no pronounced peak. This characteristic makes it suitable for basal insulin requirements. Glargine works by binding to insulin receptors, mimicking the action of endogenous insulin, thereby facilitating glucose uptake in cells.

## **Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because while Novolin N (NPH insulin) is an intermediate-acting insulin, its duration of action is significantly shorter than that of long-acting insulins like Glargine, typically lasting about 12-18 hours.
* **Option B:** This option is incorrect as Humalog (Lispro) is a rapid-acting insulin analog. It starts working within 15 minutes after injection, peaks in about 1 hour, and continues to work for 2 to 4 hours. Its short duration of action makes it unsuitable for basal insulin needs.
* **Option C:** This option is incorrect because while Levemir (Detemir) is indeed a long-acting insulin, similar to Glargine, it is not the correct answer provided.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that Glargine (Lantus) and Detemir (Levemir) are both long-acting insulins but have slightly different properties. Glargine lasts for approximately 24 hours and provides a peakless action, making it a preferred option for patients requiring a steady, long-term insulin effect.

## **Correct Answer:** . Glargine